New Delhi: India's pharmaceutical industry continues to rely heavily on China for critical raw materials, with nearly 65 per cent of its requirements for active pharmaceutical ingredients (APIs), key starting materials (KSMs), and intermediates being sourced from the neighbouring country, according to NITI Aayog.
In the eighth edition of its Trade Watch Quarterly report released on Tuesday, the government think tank highlighted persistent supply chain vulnerabilities in the sector, particularly in fermentation-based products, while also flagging rising environmental compliance costs that are increasing manufacturing and research expenses for domestic drugmakers.
